Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lupin Upbeat On Biosimilar Etanercept After Q3 Profit Plunge

Executive Summary

After a bruising financial third quarter in which net quarterly profit plunged 65%, Lupin reported “a successful outcome” for clinical trials of its rheumatoid arthritis drug etanercept, its first biosimilar product for the global market.

Related Content

Lupin-Yoshindo Stake Claim For Play In Japan Biosimilar Enbrel Market
Lupin In Tailspin After Two-In-One FDA Warning Letter
Amazon Offers Hope As US Pricing Approaches ‘Pain Point’ For Manufacturers, Says Lupin
Lupin Primes For Specialty Future With Symbiomix Acquisition
Lupin Reviews R&D Thrust, Biosimilars Plan On Course
Indian Generics Firms Must Shift Gears For Third Wave, Says Lupin MD
Lupin MD on a biosimilars play fused around Japan 'anchor'


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts